

Overview

Stellar Biotechnologies, Inc. is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Management Team

Frank Oakes

Chairman of the Board, President & Chief Executive Officer

Kathi Niffenegger, CPA

Chief Financial Officer & Corporate Secretary

Gregory T. Baxter, PhD

Executive Vice President, Corporate Development

Gary Koppenjan

Senior Director, Investor Relations and Communications

Recent News

Friday, June 07, 2019 - 09:20 AM

[Edesa Biotech and Stellar Biotechnologies Complete Business Combination](#)

Wednesday, May 08, 2019 - 07:45 AM

[Stellar Biotechnologies Reports Second Quarter Financial Results](#)

Friday, March 08, 2019 - 09:00 AM

[Stellar Biotechnologies and Edesa Biotech Sign Share Exchange Agreement](#)

Tuesday, February 05, 2019 - 04:20 PM

[Stellar Biotechnologies Reports First Quarter Financial Results](#)

Friday, November 30, 2018 - 07:30 AM

[Stellar Biotechnologies Reports Fiscal Year 2018 Financial Results](#)

DISCLAIMER


Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.

Contact Information

Stellar Biotechnologies, Inc.

332 East Scott Street
Port Hueneme, CA 93041

Nasdaq: EDSA



Share Price	\$3.99
Volume	2.14k
Shares Outstanding	7,504,468
Market Cap	\$29.94m
52 Week High	\$17.40
52 Week Low	\$3.28

as of 01/03/2020